Reactivation of Hepatitis B Virus in Hematopoietic Stem Cell Transplant Recipients in Japan: Efficacy of Nucleos(t)ide Analogues for Prevention and Treatment

被引：35

作者：

Nakamoto, Shingo ^{[1
,2
]}

Kanda, Tatsuo ^{[2
]}

Nakaseko, Chiaki ^{[3
]}

Sakaida, Emiko ^{[3
]}

Ohwada, Chikako ^{[3
]}

Takeuchi, Masahiro ^{[3
]}

Takeda, Yusuke ^{[3
]}

Mimura, Naoya ^{[3
,4
]}

Iseki, Tohru ^{[3
,4
]}

Wu, Shuang ^{[2
]}

Arai, Makoto ^{[2
]}

Imazeki, Fumio ^{[2
]}

Saito, Kengo ^{[1
]}

Shirasawa, Hiroshi ^{[1
]}

Yokosuka, Osamu ^{[2
]}

机构：

[1] Chiba Univ, Grad Sch Med, Dept Mol Virol, Chuo Ku, Chiba 2608677, Japan

[2] Chiba Univ, Grad Sch Med, Dept Gastroenterol & Nephrol, Chuo Ku, Chiba 2608677, Japan

[3] Chiba Univ Hosp, Dept Hematol, Chuo Ku, Chiba 2608670, Japan

[4] Chiba Univ Hosp, Div Transfus Med & Cell Therapy, Chuo Ku, Chiba 2608670, Japan

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2014年 / 15卷 / 11期

基金：

日本科学技术振兴机构;

关键词：

HBV; hematologic malignancy; hematopoietic stem cell; reactivation; BONE-MARROW-TRANSPLANTATION; SURFACE-ANTIGEN; REVERSE SEROCONVERSION; LAMIVUDINE; INFECTION; CHEMOTHERAPY; PROPHYLAXIS; CARRIERS; THERAPY; ANTIBODY;

D O I：

10.3390/ijms151121455

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

We retrospectively reviewed 413 recipients with hematologic malignancies who underwent hematopoietic stem cell transplantation (HSCT) between June 1986 and March 2013. Recipients with antibody to hepatitis B core antigen (anti-HBc) and/or to hepatitis B surface antigen (anti-HBs) were regarded as experiencing previous hepatitis B virus (HBV) infection. Clinical data of these recipients were reviewed from medical records. We defined >= 1 log IU/mL increase in serum HBV DNA from nadir as HBV reactivation in hepatitis B surface antigen (HBsAg)-positive recipients, and also defined >= 1 log IU/mL increase or re-appearance of HBV DNA and/or HBsAg as HBV reactivation in HBsAg-negative recipients. In 5 HBsAg-positive recipients, 2 recipients initially not administered with nucleos(t) ide analogues (NUCs) experienced HBV reactivation, but finally all 5 were successfully controlled with NUCs. HBV reactivation was observed in 11 (2.7%) of 408 HBsAg-negative recipients; 8 of these were treated with NUCs, and fortunately none developed acute liver failure. In 5 (6.0%) of 83 anti-HBc and/or anti-HBs-positive recipients, HBV reactivation occurred. None of 157 (0%) recipients without HBsAg, anti-HBs or anti-HBc experienced HBV reactivation. In HSCT recipients, HBV reactivation is a common event in HBsAg-positive recipients, or in HBsAg-negative recipients with anti-HBc and/or anti-HBs. Further attention should be paid to HSCT recipients with previous exposure to HBV.

引用

页码：21455 / 21467

页数：13

共 29 条

[1]

BEASLEY RP, 1983, LANCET, V2, P1099

[2] Hepatitis B associated liver failure following bone marrow transplantation [J].